Reply to “Performance of risk models in predicting outcomes of atezolizumab and bevacizumab therapy”

Journal of Gastroenterology 2026

View at publisher

Authors: Masayuki Ueno, Atsushi Takai, Hiroshi Seno

DOI: 10.1007/s00535-026-02381-w

Cited by: 0

References: 7

Fields of Study & Subjects

Hepatocellular Carcinoma Treatment and Prognosis Colorectal Cancer Treatments and Studies Cancer Immunotherapy and Biomarkers

References 7